Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Proton pump inhibitors and gastric neoplasia.

Literature DB >> 16905689

Proton pump inhibitors and gastric neoplasia.

Abstract

Proton pump inhibitors (PPIs) are very effective in maintaining symptomatic and endoscopic remission of acid peptic disorders, such as gastro-oesophageal reflux disease. Side effects with respect to function and morphology of the gastric mucosa are common. Helicobacter pylori eradication can partially prevent and reverse these effects without impairing PPI therapy for gastro-oesophageal reflux disease. This makes long term PPI treatment a safe therapy for patients with acid peptic disorders. The potential side effects of such therapy are discussed here.

Entities: Disease Species

Mesh：

Substances：

Year: 2006 PMID： 16905689 PMCID： PMC1860013 DOI： 10.1136/gut.2005.090514

Source DB: PubMed Journal: Gut ISSN： 0017-5749 Impact factor: 23.059

43 in total

1. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report.

Authors: P Malfertheiner; F Megraud; C O'Morain; F Bazzoli; E El-Omar; D Graham; R Hunt; T Rokkas; N Vakil; E J Kuipers
Journal: Gut Date: 2006-12-14 Impact factor: 23.059

2. Parietal cell protrusions and fundic gland cysts during omeprazole maintenance treatment.

Authors: A Cats; B E Schenk; E Bloemena; R Roosedaal; J Lindeman; I Biemond; E C Klinkenberg-Knol; S G Meuwissen; E J Kuipers
Journal: Hum Pathol Date: 2000-06 Impact factor: 3.466

3. Double gastric infection with Helicobacter pylori and non-Helicobacter pylori bacteria during acid-suppressive therapy: increase of pro-inflammatory cytokines and development of atrophic gastritis.

Authors: S Sanduleanu; D Jonkers; A De Bruïne; W Hameeteman; R W Stockbrügger
Journal: Aliment Pharmacol Ther Date: 2001-08 Impact factor: 8.171

4. Time-course of development and reversal of gastric endocrine cell hyperplasia after inhibition of acid secretion. Studies with omeprazole and ranitidine in intact and antrectomized rats.

Authors: H Larsson; E Carlsson; R Håkanson; H Mattsson; G Nilsson; R Seensalu; B Wallmark; F Sundler
Journal: Gastroenterology Date: 1988-12 Impact factor: 22.682

5. Efficacy and safety of omeprazole in the long-term treatment of peptic ulcer and reflux oesophagitis resistant to ranitidine.

Authors: G H Brunner; R Lamberts; W Creutzfeldt
Journal: Digestion Date: 1990 Impact factor: 3.216

6. Dysplasia and dysregulation of proliferation in foveolar and surface epithelia of fundic gland polyps from patients with familial adenomatous polyposis.

Authors: T T Wu; S Kornacki; A Rashid; J H Yardley; S R Hamilton
Journal: Am J Surg Pathol Date: 1998-03 Impact factor: 6.394

7. Empirical use of antisecretory drug therapy delays diagnosis of upper gastrointestinal adenocarcinoma but does not effect outcome.

Authors: S J Panter; H O'Flanagan; M G Bramble; A P S Hungin
Journal: Aliment Pharmacol Ther Date: 2004-05-01 Impact factor: 8.171

8. Argyrophil cell hyperplasia associated with chronic corpus gastritis in gastric ulcer disease.

Authors: N Havu; H I Maaroos; P Sipponen
Journal: Scand J Gastroenterol Suppl Date: 1991

9. Gastric endocrine cells and gastritis in patients receiving long-term omeprazole treatment.

Authors: E Solcia; R Fiocca; N Havu; A Dalväg; R Carlsson
Journal: Digestion Date: 1992 Impact factor: 3.216

10. Detection of upper gastrointestinal cancer in patients taking antisecretory therapy prior to gastroscopy.

Authors: M G Bramble; Z Suvakovic; A P Hungin
Journal: Gut Date: 2000-04 Impact factor: 23.059

28 in total

Review 1. Potential adverse effects of proton pump inhibitors.

Authors: Gregory A Coté; Colin W Howden
Journal: Curr Gastroenterol Rep Date: 2008-06

Review 2. Proton pump inhibitors: an update of their clinical use and pharmacokinetics.

Authors: Shaojun Shi; Ulrich Klotz
Journal: Eur J Clin Pharmacol Date: 2008-08-05 Impact factor: 2.953

Review 3. Clinical Implications of Emerging Data on the Safety of Proton Pump Inhibitors.

Authors: Felice Schnoll-Sussman; Philip O Katz
Journal: Curr Treat Options Gastroenterol Date: 2017-03

4. Systems biology analysis of omeprazole therapy in cirrhosis demonstrates significant shifts in gut microbiota composition and function.

Authors: Jasmohan S Bajaj; I Jane Cox; Naga S Betrapally; Douglas M Heuman; Mitchell L Schubert; Maiyuran Ratneswaran; Phillip B Hylemon; Melanie B White; Kalyani Daita; Nicole A Noble; Masoumeh Sikaroodi; Roger Williams; Mary M E Crossey; Simon D Taylor-Robinson; Patrick M Gillevet
Journal: Am J Physiol Gastrointest Liver Physiol Date: 2014-09-25 Impact factor: 4.052

5. Divergent trends for gastric cancer incidence by anatomical subsite in US adults.

Authors: M Constanza Camargo; William F Anderson; Jessica B King; Pelayo Correa; Cheryll C Thomas; Philip S Rosenberg; Christie R Eheman; Charles S Rabkin
Journal: Gut Date: 2011-05-25 Impact factor: 23.059

Review 6. Adverse effects of long-term proton pump inhibitor therapy.

Authors: Edward Sheen; George Triadafilopoulos
Journal: Dig Dis Sci Date: 2011-03-02 Impact factor: 3.199

Review 7. Potential mechanism of corpus-predominant gastritis after PPI therapy in Helicobacter pylori-positive patients with GERD.

Authors: Ken-ichi Mukaisho; Tadashi Hagiwara; Takahisa Nakayama; Takanori Hattori; Hiroyuki Sugihara
Journal: World J Gastroenterol Date: 2014-09-14 Impact factor: 5.742